Rare phylotypes in stone, stool, and urine microbiomes are associated with urinary stone diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated how rare, low-abundance bacterial phylotypes contribute to the microbial communities associated with urinary stone disease (USD), rather than focusing only on dominant, common taxa. The researchers conducted a meta-analysis of existing 16S rRNA sequencing datasets derived from kidney stone, stool, and urine samples. They separated bacterial taxa into rare and common groups based on the frequency and abundance of amplicon sequence variants, then compared how each group related to disease status across the three sample types. The aim was to clarify the distinct contribution of rare phylotypes to the gut, upper urinary, and lower urinary tract microbiomes in USD.
Who was studied?
The analysis drew on previously generated 16S rRNA datasets from participants with and without urinary stone disease, pooled across stone, stool, and urine sample types. The abstract does not specify exact participant numbers, ages, or geographic origin, so this appears to be a secondary meta-analysis of existing public or previously published cohort data rather than a newly recruited cohort. What can be said with confidence is that the population included both USD patients and comparison individuals without the disease.
What were the most important findings?
Consistent with prior work, the gut, upper urinary tract, and lower urinary tract microbiomes were each found to be distinct microbial communities. Rare phylotypes, those present at low frequency and abundance, comprised the majority of the taxa detected across kidney stone, stool, and urine samples. This indicates that the low-abundance portion of these communities is numerically dominant even though it is often overlooked in favor of common, high-abundance taxa. The abstract does not report findings related to Desulfovibrio, sulfate-reducing bacteria, hydrogen sulfide, or sulfur metabolism.
What are the greatest implications of this study?
The findings suggest that rare phylotypes deserve dedicated attention in future USD microbiome research, since they make up most of the taxonomic diversity across stone, stool, and urine niches. Because bacteriotherapies for urologic health are being developed based on microbiome composition, ignoring rare taxa could mean missing organisms relevant to disease onset or progression. This work supports a shift toward analytical approaches that explicitly separate rare from common phylotypes when characterizing the kidney stone, gut, and urinary tract microbiome relationship to USD.